Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Rheumatology (Oxford, England)|August 13, 2021
Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment responseButsabong Lerkvaleekul, Saskia R Veldkamp, M Marlot van der Wal, et al.
Nature Immunology|January 5, 2023
Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activationYing-Yin Chao, Alisa Puhach, David Frieser, et al.
JCI Insight|June 8, 2026
LDL receptor-mediated lipoprotein uptake fuels human CD4+ T cell polarization toward a c-MAF/IL-10- and FOXP3-driven phenotypeAngela Markovska, Niels S van Heusden, Dagmar Duijzer, et al.
Arthritis Care & Research|December 17, 2013
Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritisFriederike Rothmund, Joachim Gerss, Nicolino Ruperto, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyNienke M Ter Haar, E H Pieter van Dijkhuizen, Joost F Swart, et al.
Journal of Leukocyte Biology|April 24, 2024
N6-methyladenosine promotes TNF mRNA degradation in CD4+ T lymphocytesEllen C N van Vroonhoven, Lucas W Picavet, Rianne C Scholman, et al.
Annals of the Rheumatic Diseases|May 6, 2017
European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiativeNoortje Groot, Nienke de Graeff, Tadej Avcin, et al.
Annals of the Rheumatic Diseases|January 29, 2015
Evidence-based recommendations for genetic diagnosis of familial Mediterranean feverGabriella Giancane, Nienke M Ter Haar, Nico Wulffraat, et al.
Rheumatology (Oxford, England)|September 5, 2023
Management of adult-onset Still's disease: evidence- and consensus-based recommendations by expertsHelen L Leavis, Paul L A van Daele, Catharina Mulders-Manders, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 20, 2023
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN VariantsRemco G A Erkens, Jorg J A Calis, Anouk Verwoerd, et al.
Pageof 9